US20030109566A1 - Remedial agent for optic nerve disease and the like - Google Patents

Remedial agent for optic nerve disease and the like Download PDF

Info

Publication number
US20030109566A1
US20030109566A1 US10/312,502 US31250202A US2003109566A1 US 20030109566 A1 US20030109566 A1 US 20030109566A1 US 31250202 A US31250202 A US 31250202A US 2003109566 A1 US2003109566 A1 US 2003109566A1
Authority
US
United States
Prior art keywords
retinal
optic nerve
medicament
therapeutic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/312,502
Other languages
English (en)
Inventor
Tomiya Mano
Shunji Sogou
Eri Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Assigned to MITSUBISHI PHARMA CORPORATION reassignment MITSUBISHI PHARMA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INOUE, ERI, MANO, TOMIYA, SOGOU, SHUNJI
Publication of US20030109566A1 publication Critical patent/US20030109566A1/en
Priority to US11/477,854 priority Critical patent/US7638516B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/312,502 2000-06-29 2001-06-28 Remedial agent for optic nerve disease and the like Abandoned US20030109566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/477,854 US7638516B2 (en) 2000-06-29 2006-06-30 Agent for therapeutic treatment of optic nerve diseases and the like

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000197250 2000-06-29
JP2000-197250 2000-06-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/477,854 Continuation US7638516B2 (en) 2000-06-29 2006-06-30 Agent for therapeutic treatment of optic nerve diseases and the like

Publications (1)

Publication Number Publication Date
US20030109566A1 true US20030109566A1 (en) 2003-06-12

Family

ID=18695597

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/312,502 Abandoned US20030109566A1 (en) 2000-06-29 2001-06-28 Remedial agent for optic nerve disease and the like
US11/477,854 Expired - Fee Related US7638516B2 (en) 2000-06-29 2006-06-30 Agent for therapeutic treatment of optic nerve diseases and the like

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/477,854 Expired - Fee Related US7638516B2 (en) 2000-06-29 2006-06-30 Agent for therapeutic treatment of optic nerve diseases and the like

Country Status (8)

Country Link
US (2) US20030109566A1 (de)
EP (1) EP1297849B1 (de)
JP (1) JPWO2002000260A1 (de)
AT (1) ATE428470T1 (de)
AU (1) AU2001267864A1 (de)
CA (1) CA2414586C (de)
DE (1) DE60138385D1 (de)
WO (1) WO2002000260A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162330A1 (en) * 2001-05-11 2004-08-19 Hiroshi Yoshida Stable high-concentration injection containing pyrazolone derivative
WO2005055926A3 (en) * 2003-11-20 2006-12-07 Othera Pharmaceuticals Inc Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7442711B2 (en) 2002-05-17 2008-10-28 Othera Holding, Inc. Amelioration of the development of cataracts and other ophthalmic diseases
US7825134B2 (en) 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266062A1 (en) * 2002-11-05 2005-12-01 Lead Ch Emical Co., Ltd. Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
WO2007055312A1 (ja) * 2005-11-10 2007-05-18 Mitsubishi Tanabe Pharma Corporation ピラゾロン化合物含有水溶液が充填されたプラスチック容器
JP5509090B2 (ja) * 2007-11-21 2014-06-04 テイコク ファーマ ユーエスエー インコーポレーテッド ピラゾロン誘導体のエマルジョン製剤
JP5591720B2 (ja) 2009-01-29 2014-09-17 株式会社林原 抗神経変性疾患剤
JP2017222575A (ja) 2014-09-19 2017-12-21 田辺三菱製薬株式会社 眼科疾患予防治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837723A (en) * 1993-07-07 1998-11-17 Mitsubishi Chemical Corporation Pharmaceutical composition useful for treating ophthalmological diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533662A1 (de) * 1984-09-20 1986-03-27 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kombination von 1-phenyl-4-alkylpyrazolidindion-3,5-derivaten mit einem starken reduktionsmittel fuer die herstellung eines topischen entzuendungshemmenden arzneimittels fuer augen
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPS62108814A (ja) 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd 過酸化脂質生成抑制剤
DK169672B1 (da) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
FR2608045B1 (fr) 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
JP2906512B2 (ja) * 1990-01-16 1999-06-21 三菱化学株式会社 抗潰瘍剤
WO1993000088A1 (de) * 1991-06-24 1993-01-07 Hoechst Aktiengesellschaft Verwendung von phenylpyrazolin-derivaten zur behandlung von erhöhtem augeninnendruck
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
JPH09278652A (ja) * 1996-04-05 1997-10-28 Sumitomo Pharmaceut Co Ltd 網膜疾患治療剤
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
JPH10218771A (ja) * 1997-02-05 1998-08-18 Ishihara Sangyo Kaisha Ltd ピラゾロン系化合物またはその塩を含有する血小板由来血管内皮細胞増殖因子活性阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837723A (en) * 1993-07-07 1998-11-17 Mitsubishi Chemical Corporation Pharmaceutical composition useful for treating ophthalmological diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162330A1 (en) * 2001-05-11 2004-08-19 Hiroshi Yoshida Stable high-concentration injection containing pyrazolone derivative
US7211596B2 (en) 2001-05-11 2007-05-01 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
US7442711B2 (en) 2002-05-17 2008-10-28 Othera Holding, Inc. Amelioration of the development of cataracts and other ophthalmic diseases
US8383648B2 (en) 2002-05-17 2013-02-26 Colby Pharmaceutical Company Amelioration of the development of cataracts and other ophthalmic diseases
US7825134B2 (en) 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2005055926A3 (en) * 2003-11-20 2006-12-07 Othera Pharmaceuticals Inc Amelioration of cataracts, macular degeneration and other ophthalmic diseases

Also Published As

Publication number Publication date
CA2414586C (en) 2009-09-29
ATE428470T1 (de) 2009-05-15
US7638516B2 (en) 2009-12-29
CA2414586A1 (en) 2002-12-30
US20060247293A1 (en) 2006-11-02
EP1297849A4 (de) 2006-10-18
WO2002000260A1 (fr) 2002-01-03
EP1297849A1 (de) 2003-04-02
DE60138385D1 (de) 2009-05-28
AU2001267864A1 (en) 2002-01-08
JPWO2002000260A1 (ja) 2004-01-08
EP1297849B1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
US7638516B2 (en) Agent for therapeutic treatment of optic nerve diseases and the like
JP7079243B2 (ja) 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
US20040216749A1 (en) Vasomodulation during glaucoma surgery
US20050250788A1 (en) Aqueous outflow enhancement with vasodilated aqueous cavity
JP4972552B2 (ja) 緑内障を予防又は治療する薬剤
JP2008308489A (ja) ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
EP2114398B1 (de) Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
US5837723A (en) Pharmaceutical composition useful for treating ophthalmological diseases
JPWO2008093691A1 (ja) 網膜神経又は視神経の保護剤
EP1884237B1 (de) Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom
US5506241A (en) Argatroban preparations for ophthalmic use
WO2016182032A1 (ja) アゾール系抗真菌薬の眼瞼皮膚への投与
AU668710B2 (en) Argatroban preparations for ophthalmic use
EP4052694A1 (de) Augentropfenzusammensetzung zum vorbeugen oder behandeln von augenkrankheiten
EP0968716A1 (de) Arzneimittel zur behandlung von augenkreislauferkrankungen
JP2004331502A (ja) 視神経細胞保護剤
JP3530542B2 (ja) 眼科用アルガトロバン製剤
US20040067891A1 (en) Therapeutic and/or preventive agents for diseases due to retinal ischemia
JP4393863B2 (ja) 視神経細胞保護剤
EP1346728A1 (de) Ophthalmologische zubereitungen
JP2004250347A (ja) 網膜虚血に基づく疾患の治療および／又は予防剤
JP2001240543A (ja) 虚血性網膜疾患並びに網膜及び視神経障害の治療及び／または予防薬
JPH10316571A (ja) 眼循環障害改善剤
KR20000016784A (ko) 안 순환 장해 개선제
WO2016010131A1 (ja) 加齢黄斑変性の予防または治療剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: MITSUBISHI PHARMA CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANO, TOMIYA;SOGOU, SHUNJI;INOUE, ERI;REEL/FRAME:013731/0459

Effective date: 20021218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION